ID   1433Z_HUMAN             Reviewed;         245 AA.
AC   P63104; A8K1N0; B7Z465; P29213; P29312; Q32P43; Q5XJ08; Q6GPI2; Q6IN74;
AC   Q6NUR9; Q6P3U9; Q86V33;
DT   13-SEP-2004, integrated into UniProtKB/Swiss-Prot.
DT   13-SEP-2004, sequence version 1.
DT   07-APR-2021, entry version 198.
DE   RecName: Full=14-3-3 protein zeta/delta;
DE   AltName: Full=Protein kinase C inhibitor protein 1;
DE            Short=KCIP-1;
GN   Name=YWHAZ;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=1577711;
RA   Zupan L.A., Steffens D.L., Berry C.A., Landt M.L., Gross R.W.;
RT   "Cloning and expression of a human 14-3-3 protein mediating
RT   phospholipolysis. Identification of an arachidonoyl-enzyme intermediate
RT   during catalysis.";
RL   J. Biol. Chem. 267:8707-8710(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Bone marrow;
RX   PubMed=9512661; DOI=10.1016/s0167-4781(97)00171-1;
RA   Seluja G.A., Pietromonaco S.F., Elias L.;
RT   "Two unique 5' untranslated regions in mRNAs encoding human 14-3-3 zeta:
RT   differential expression in hemopoietic cells.";
RL   Biochim. Biophys. Acta 1395:281-287(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Hippocampus, and Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain, Colon, Eye, Melanoma, PNS, Skin, Testis, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 1-18.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A., Thomas G.R.,
RA   Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass spectrometric
RT   identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [7]
RP   PROTEIN SEQUENCE OF 1-9; 12-49; 57-74; 84-103; 128-158 AND 194-222,
RP   INTERACTION WITH PI4KB; TBC1D22A AND TBC1D22B, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=23572552; DOI=10.1128/mbio.00098-13;
RA   Greninger A.L., Knudsen G.M., Betegon M., Burlingame A.L., DeRisi J.L.;
RT   "ACBD3 interaction with TBC1 domain 22 protein is differentially affected
RT   by enteroviral and kobuviral 3A protein binding.";
RL   MBio 4:E00098-E00098(2013).
RN   [8]
RP   PROTEIN SEQUENCE OF 1-9; 12-18; 28-49; 61-68; 86-91; 128-158 AND 213-222,
RP   ACETYLATION AT MET-1, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=B-cell lymphoma, and Platelet;
RA   Bienvenut W.V., Potts A., Barblan J., Claeys D., Quadroni M.;
RL   Submitted (NOV-2005) to UniProtKB.
RN   [9]
RP   PROTEIN SEQUENCE OF 92-103; 140-157; 194-212 AND 223-245, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Afjehi-Sadat L., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [10]
RP   PHOSPHORYLATION AT THR-232, INTERACTION WITH RAF1, AND FUNCTION.
RX   PubMed=9360956; DOI=10.1074/jbc.272.46.28882;
RA   Dubois T., Rommel C., Howell S., Steinhussen U., Soneji Y., Morrice N.,
RA   Moelling K., Aitken A.;
RT   "14-3-3 is phosphorylated by casein kinase I on residue 233.
RT   Phosphorylation at this site in vivo regulates Raf/14-3-3 interaction.";
RL   J. Biol. Chem. 272:28882-28888(1997).
RN   [11]
RP   INTERACTION WITH TLK2.
RX   PubMed=10455159; DOI=10.1074/jbc.274.35.24865;
RA   Zhang S., Xing H., Muslin A.J.;
RT   "Nuclear localization of protein kinase U-alpha is regulated by 14-3-3.";
RL   J. Biol. Chem. 274:24865-24872(1999).
RN   [12]
RP   INTERACTION WITH AANAT.
RX   PubMed=11427721; DOI=10.1073/pnas.141118798;
RA   Ganguly S., Gastel J.A., Weller J.L., Schwartz C., Jaffe H.,
RA   Namboodiri M.A., Coon S.L., Hickman A.B., Rollag M., Obsil T.,
RA   Beauverger P., Ferry G., Boutin J.A., Klein D.C.;
RT   "Role of a pineal cAMP-operated arylalkylamine N-acetyltransferase/14-3-3-
RT   binding switch in melatonin synthesis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8083-8088(2001).
RN   [13]
RP   PHOSPHORYLATION AT SER-58, AND INTERACTION WITH AKT1.
RX   PubMed=11956222; DOI=10.1074/jbc.m203167200;
RA   Powell D.W., Rane M.J., Chen Q., Singh S., McLeish K.R.;
RT   "Identification of 14-3-3zeta as a protein kinase B/Akt substrate.";
RL   J. Biol. Chem. 277:21639-21642(2002).
RN   [14]
RP   PHOSPHORYLATION AT SER-58, AND DIMERIZATION.
RX   PubMed=12865427; DOI=10.1074/jbc.m304689200;
RA   Woodcock J.M., Murphy J., Stomski F.C., Berndt M.C., Lopez A.F.;
RT   "The dimeric versus monomeric status of 14-3-3zeta is controlled by
RT   phosphorylation of Ser58 at the dimer interface.";
RL   J. Biol. Chem. 278:36323-36327(2003).
RN   [15]
RP   INTERACTION WITH AANAT, AND FUNCTION.
RX   PubMed=14578935; DOI=10.1038/nsb1005;
RA   Zheng W., Zhang Z., Ganguly S., Weller J.L., Klein D.C., Cole P.A.;
RT   "Cellular stabilization of the melatonin rhythm enzyme induced by
RT   nonhydrolyzable phosphonate incorporation.";
RL   Nat. Struct. Biol. 10:1054-1057(2003).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Lymphoblast;
RX   PubMed=14654843; DOI=10.1038/nature02166;
RA   Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A., Mann M.;
RT   "Proteomic characterization of the human centrosome by protein correlation
RT   profiling.";
RL   Nature 426:570-574(2003).
RN   [17]
RP   PHOSPHORYLATION AT SER-184, INTERACTION WITH BAX, FUNCTION, AND MUTAGENESIS
RP   OF SER-184.
RX   PubMed=15071501; DOI=10.1038/sj.emboj.7600194;
RA   Tsuruta F., Sunayama J., Mori Y., Hattori S., Shimizu S., Tsujimoto Y.,
RA   Yoshioka K., Masuyama N., Gotoh Y.;
RT   "JNK promotes Bax translocation to mitochondria through phosphorylation of
RT   14-3-3 proteins.";
RL   EMBO J. 23:1889-1899(2004).
RN   [18]
RP   INTERACTION WITH SSH1.
RX   PubMed=15159416; DOI=10.1083/jcb.200401136;
RA   Nagata-Ohashi K., Ohta Y., Goto K., Chiba S., Mori R., Nishita M.,
RA   Ohashi K., Kousaka K., Iwamatsu A., Niwa R., Uemura T., Mizuno K.;
RT   "A pathway of neuregulin-induced activation of cofilin-phosphatase
RT   Slingshot and cofilin in lamellipodia.";
RL   J. Cell Biol. 165:465-471(2004).
RN   [19]
RP   INTERACTION WITH MLLT7.
RX   PubMed=16114898; DOI=10.1021/bi050618r;
RA   Obsilova V., Vecer J., Herman P., Pabianova A., Sulc M., Teisinger J.,
RA   Boura E., Obsil T.;
RT   "14-3-3 protein interacts with nuclear localization sequence of forkhead
RT   transcription factor FoxO4.";
RL   Biochemistry 44:11608-11617(2005).
RN   [20]
RP   INTERACTION WITH SSH1.
RX   PubMed=15660133; DOI=10.1038/sj.emboj.7600543;
RA   Soosairajah J., Maiti S., Wiggan O., Sarmiere P., Moussi N., Sarcevic B.,
RA   Sampath R., Bamburg J.R., Bernard O.;
RT   "Interplay between components of a novel LIM kinase-slingshot phosphatase
RT   complex regulates cofilin.";
RL   EMBO J. 24:473-486(2005).
RN   [21]
RP   PHOSPHORYLATION AT SER-58, AND MUTAGENESIS OF SER-58.
RX   PubMed=15883165; DOI=10.1074/jbc.m409081200;
RA   Ma Y., Pitson S., Hercus T., Murphy J., Lopez A., Woodcock J.;
RT   "Sphingosine activates protein kinase A type II by a novel cAMP-independent
RT   mechanism.";
RL   J. Biol. Chem. 280:26011-26017(2005).
RN   [22]
RP   INTERACTION WITH ABL1, IDENTIFICATION BY MASS SPECTROMETRY, PHOSPHORYLATION
RP   AT SER-184, AND MUTAGENESIS OF SER-184.
RX   PubMed=15696159; DOI=10.1038/ncb1228;
RA   Yoshida K., Yamaguchi T., Natsume T., Kufe D., Miki Y.;
RT   "JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of c-
RT   Abl in the apoptotic response to DNA damage.";
RL   Nat. Cell Biol. 7:278-285(2005).
RN   [23]
RP   INTERACTION WITH AANAT, AND FUNCTION.
RX   PubMed=15644438; DOI=10.1073/pnas.0406871102;
RA   Ganguly S., Weller J.L., Ho A., Chemineau P., Malpaux B., Klein D.C.;
RT   "Melatonin synthesis: 14-3-3-dependent activation and inhibition of
RT   arylalkylamine N-acetyltransferase mediated by phosphoserine-205.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:1222-1227(2005).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [25]
RP   PHOSPHORYLATION AT SER-58, DIMERIZATION, INTERACTION WITH TP53 AND YWHAE,
RP   FUNCTION, AND MUTAGENESIS OF SER-58.
RX   PubMed=16376338; DOI=10.1016/j.febslet.2005.12.024;
RA   Gu Y.-M., Jin Y.-H., Choi J.-K., Baek K.-H., Yeo C.-Y., Lee K.-Y.;
RT   "Protein kinase A phosphorylates and regulates dimerization of 14-3-3
RT   epsilon.";
RL   FEBS Lett. 580:305-310(2006).
RN   [26]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=17081065; DOI=10.1021/pr060363j;
RA   Chi A., Valencia J.C., Hu Z.-Z., Watabe H., Yamaguchi H., Mangini N.J.,
RA   Huang H., Canfield V.A., Cheng K.C., Yang F., Abe R., Yamagishi S.,
RA   Shabanowitz J., Hearing V.J., Wu C., Appella E., Hunt D.F.;
RT   "Proteomic and bioinformatic characterization of the biogenesis and
RT   function of melanosomes.";
RL   J. Proteome Res. 5:3135-3144(2006).
RN   [27]
RP   FUNCTION, INTERACTION WITH AK5; LDB1; MADD; MARK3; PDE1A AND SMARCB1, AND
RP   MUTAGENESIS OF 56-ARG--ARG-60.
RX   PubMed=16959763; DOI=10.1074/mcp.m600147-mcp200;
RA   Angrand P.O., Segura I., Voelkel P., Ghidelli S., Terry R., Brajenovic M.,
RA   Vintersten K., Klein R., Superti-Furga G., Drewes G., Kuster B.,
RA   Bouwmeester T., Acker-Palmer A.;
RT   "Transgenic mouse proteomics identifies new 14-3-3-associated proteins
RT   involved in cytoskeletal rearrangements and cell signaling.";
RL   Mol. Cell. Proteomics 5:2211-2227(2006).
RN   [28]
RP   INTERACTION WITH NOXA1, AND MUTAGENESIS OF LYS-49.
RX   PubMed=17913709; DOI=10.1074/jbc.m704754200;
RA   Kim J.-S., Diebold B.A., Babior B.M., Knaus U.G., Bokoch G.M.;
RT   "Regulation of Nox1 activity via PKA-mediated phosphorylation of NoxA1 and
RT   14-3-3 binding.";
RL   J. Biol. Chem. 282:34787-34800(2007).
RN   [29]
RP   INTERACTION WITH ARHGEF2.
RX   PubMed=14970201; DOI=10.1074/jbc.m400084200;
RA   Zenke F.T., Krendel M., DerMardirossian C., King C.C., Bohl B.P.,
RA   Bokoch G.M.;
RT   "p21-activated kinase 1 phosphorylates and regulates 14-3-3 binding to GEF-
RT   H1, a microtubule-localized Rho exchange factor.";
RL   J. Biol. Chem. 279:18392-18400(2004).
RN   [30]
RP   INTERACTION WITH GAB2.
RX   PubMed=19172738; DOI=10.1038/emboj.2008.159;
RA   Brummer T., Larance M., Herrera Abreu M.T., Lyons R.J., Timpson P.,
RA   Emmerich C.H., Fleuren E.D.G., Lehrbach G.M., Schramek D., Guilhaus M.,
RA   James D.E., Daly R.J.;
RT   "Phosphorylation-dependent binding of 14-3-3 terminates signalling by the
RT   Gab2 docking protein.";
RL   EMBO J. 27:2305-2316(2008).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [32]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [33]
RP   INTERACTION WITH SLITRK1.
RX   PubMed=19640509; DOI=10.1016/j.biopsych.2009.05.033;
RA   Kajiwara Y., Buxbaum J.D., Grice D.E.;
RT   "SLITRK1 binds 14-3-3 and regulates neurite outgrowth in a phosphorylation-
RT   dependent manner.";
RL   Biol. Psychiatry 66:918-925(2009).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-207, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [35]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-3 AND LYS-68, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [36]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-207 AND THR-232, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [37]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [38]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [39]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [40]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [41]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [42]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [43]
RP   INTERACTION WITH DAPK2.
RX   PubMed=26047703; DOI=10.1016/j.bbrc.2015.05.105;
RA   Yuasa K., Ota R., Matsuda S., Isshiki K., Inoue M., Tsuji A.;
RT   "Suppression of death-associated protein kinase 2 by interaction with 14-3-
RT   3 proteins.";
RL   Biochem. Biophys. Res. Commun. 464:70-75(2015).
RN   [44]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS).
RX   PubMed=10488331; DOI=10.1016/s1097-2765(00)80363-9;
RA   Rittinger K., Budman J., Xu J., Volinia S., Cantley L.C., Smerdon S.J.,
RA   Gamblin S.J., Yaffe M.B.;
RT   "Structural analysis of 14-3-3 phosphopeptide complexes identifies a dual
RT   role for the nuclear export signal of 14-3-3 in ligand binding.";
RL   Mol. Cell 4:153-166(1999).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) IN COMPLEX WITH AANAT.
RX   PubMed=11336675; DOI=10.1016/s0092-8674(01)00316-6;
RA   Obsil T., Ghirlando R., Klein D.C., Ganguly S., Dyda F.;
RT   "Crystal structure of the 14-3-3zeta:serotonin N-acetyltransferase complex.
RT   a role for scaffolding in enzyme regulation.";
RL   Cell 105:257-267(2001).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) IN COMPLEX WITH HISTONE H3
RP   PHOSPHOPEPTIDE.
RX   PubMed=16246723; DOI=10.1016/j.molcel.2005.08.032;
RA   Macdonald N., Welburn J.P.I., Noble M.E.M., Nguyen A., Yaffe M.B.,
RA   Clynes D., Moggs J.G., Orphanides G., Thomson S., Edmunds J.W.,
RA   Clayton A.L., Endicott J.A., Mahadevan L.C.;
RT   "Molecular basis for the recognition of phosphorylated and
RT   phosphoacetylated histone h3 by 14-3-3.";
RL   Mol. Cell 20:199-211(2005).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 1-230 IN COMPLEX WITH PSEUDOMONAS
RP   AERUGINOSA EXOS.
RX   PubMed=17235285; DOI=10.1038/sj.emboj.7601530;
RA   Ottmann C., Yasmin L., Weyand M., Veesenmeyer J.L., Diaz M.H., Palmer R.H.,
RA   Francis M.S., Hauser A.R., Wittinghofer A., Hallberg B.;
RT   "Phosphorylation-independent interaction between 14-3-3 and exoenzyme S:
RT   from structure to pathogenesis.";
RL   EMBO J. 26:902-913(2007).
RN   [49]
RP   VARIANTS 14-GLU--ASN-245 DEL; ARG-53; LEU-145 AND TRP-230, CHARACTERIZATION
RP   OF VARIANT TRP-230, FUNCTION, INTERACTION WITH BRAF AND RAF1,
RP   PHOSPHORYLATION AT THR-232 BY CK1, AND MUTAGENESIS OF THR-232.
RX   PubMed=31024343; DOI=10.3389/fphys.2019.00388;
RA   Popov I.K., Hiatt S.M., Whalen S., Keren B., Ruivenkamp C.,
RA   van Haeringen A., Chen M.J., Cooper G.M., Korf B.R., Chang C.;
RT   "A YWHAZ variant associated with cardiofaciocutaneous syndrome activates
RT   the RAF-ERK pathway.";
RL   Front. Physiol. 10:388-388(2019).
CC   -!- FUNCTION: Adapter protein implicated in the regulation of a large
CC       spectrum of both general and specialized signaling pathways. Binds to a
CC       large number of partners, usually by recognition of a phosphoserine or
CC       phosphothreonine motif. Binding generally results in the modulation of
CC       the activity of the binding partner. Induces ARHGEF7 activity on RAC1
CC       as well as lamellipodia and membrane ruffle formation
CC       (PubMed:16959763). In neurons, regulates spine maturation through the
CC       modulation of ARHGEF7 activity (By similarity).
CC       {ECO:0000250|UniProtKB:O55043, ECO:0000269|PubMed:14578935,
CC       ECO:0000269|PubMed:15071501, ECO:0000269|PubMed:15644438,
CC       ECO:0000269|PubMed:16376338, ECO:0000269|PubMed:16959763,
CC       ECO:0000269|PubMed:31024343, ECO:0000269|PubMed:9360956}.
CC   -!- SUBUNIT: Interacts with CDK16 and BSPRY (By similarity). Interacts with
CC       WEE1 (C-terminal). Interacts with SAMSN1 (By similarity). Interacts
CC       with MLF1 (phosphorylated form); the interaction retains it in the
CC       cytoplasm (By similarity). Interacts with Thr-phosphorylated ITGB2 (By
CC       similarity). Interacts with BCL2L11 (By similarity). Homodimer.
CC       Heterodimerizes with YWHAE. Homo- and heterodimerization is inhibited
CC       by phosphorylation on Ser-58. Interacts with FOXO4, NOXA1, SSH1 and
CC       ARHGEF2. Interacts with Pseudomonas aeruginosa exoS (unphosphorylated
CC       form). Interacts with BAX; the interaction occurs in the cytoplasm.
CC       Under stress conditions, MAPK8-mediated phosphorylation releases BAX to
CC       mitochondria. Interacts with phosphorylated RAF1; the interaction is
CC       inhibited when YWHAZ is phosphorylated on Thr-232 (PubMed:31024343).
CC       Interacts with BRAF (PubMed:31024343). Interacts with TP53; the
CC       interaction enhances p53 transcriptional activity. The Ser-58
CC       phosphorylated form inhibits this interaction and p53 transcriptional
CC       activity. Interacts with ABL1 (phosphorylated form); the interaction
CC       retains ABL1 in the cytoplasm. Interacts with PKA-phosphorylated AANAT;
CC       the interaction modulates AANAT enzymatic activity by increasing
CC       affinity for arylalkylamines and acetyl-CoA and protecting the enzyme
CC       from dephosphorylation and proteasomal degradation. It may also prevent
CC       thiol-dependent inactivation. Interacts with AKT1; the interaction
CC       phosphorylates YWHAZ and modulates dimerization. Interacts with GAB2
CC       and TLK2. Interacts with the 'Thr-369' phosphorylated form of DAPK2
CC       (PubMed:26047703). Interacts with PI4KB, TBC1D22A and TBC1D22B
CC       (PubMed:23572552). Interacts with ZFP36L1 (via phosphorylated form);
CC       this interaction occurs in a p38 MAPK- and AKT-signaling pathways (By
CC       similarity). Interacts with SLITRK1 (PubMed:19640509). Interacts with
CC       AK5, LDB1, MADD, MARK3, PDE1A and SMARCB1 (PubMed:16959763).
CC       {ECO:0000250|UniProtKB:P63101, ECO:0000250|UniProtKB:Q9ES28,
CC       ECO:0000269|PubMed:10455159, ECO:0000269|PubMed:11336675,
CC       ECO:0000269|PubMed:11427721, ECO:0000269|PubMed:11956222,
CC       ECO:0000269|PubMed:14578935, ECO:0000269|PubMed:14970201,
CC       ECO:0000269|PubMed:15071501, ECO:0000269|PubMed:15159416,
CC       ECO:0000269|PubMed:15644438, ECO:0000269|PubMed:15660133,
CC       ECO:0000269|PubMed:15696159, ECO:0000269|PubMed:16114898,
CC       ECO:0000269|PubMed:16246723, ECO:0000269|PubMed:16376338,
CC       ECO:0000269|PubMed:16959763, ECO:0000269|PubMed:17235285,
CC       ECO:0000269|PubMed:17913709, ECO:0000269|PubMed:19172738,
CC       ECO:0000269|PubMed:19640509, ECO:0000269|PubMed:23572552,
CC       ECO:0000269|PubMed:26047703, ECO:0000269|PubMed:31024343,
CC       ECO:0000269|PubMed:9360956}.
CC   -!- INTERACTION:
CC       P63104; P00519: ABL1; NbExp=3; IntAct=EBI-347088, EBI-375543;
CC       P63104; P60709: ACTB; NbExp=3; IntAct=EBI-347088, EBI-353944;
CC       P63104; Q9P0K1: ADAM22; NbExp=3; IntAct=EBI-347088, EBI-1567236;
CC       P63104; Q9P0K1-3: ADAM22; NbExp=3; IntAct=EBI-347088, EBI-1567267;
CC       P63104; Q12802: AKAP13; NbExp=2; IntAct=EBI-347088, EBI-1373806;
CC       P63104; P10398: ARAF; NbExp=6; IntAct=EBI-347088, EBI-365961;
CC       P63104; Q5T5U3: ARHGAP21; NbExp=2; IntAct=EBI-347088, EBI-1642518;
CC       P63104; Q5VV41: ARHGEF16; NbExp=2; IntAct=EBI-347088, EBI-1057448;
CC       P63104; Q92974: ARHGEF2; NbExp=3; IntAct=EBI-347088, EBI-302405;
CC       P63104; P25705: ATP5F1A; NbExp=3; IntAct=EBI-347088, EBI-351437;
CC       P63104; P06576: ATP5F1B; NbExp=2; IntAct=EBI-347088, EBI-356231;
CC       P63104; P54253: ATXN1; NbExp=8; IntAct=EBI-347088, EBI-930964;
CC       P63104; Q92934: BAD; NbExp=8; IntAct=EBI-347088, EBI-700771;
CC       P63104; Q9UQB8: BAIAP2; NbExp=3; IntAct=EBI-347088, EBI-525456;
CC       P63104; P15056: BRAF; NbExp=8; IntAct=EBI-347088, EBI-365980;
CC       P63104; P0DP25: CALM3; NbExp=2; IntAct=EBI-347088, EBI-397435;
CC       P63104; O00257-3: CBX4; NbExp=2; IntAct=EBI-347088, EBI-4392727;
CC       P63104; Q9Y3M2: CBY1; NbExp=3; IntAct=EBI-347088, EBI-947308;
CC       P63104; Q86Z20: CCDC125; NbExp=3; IntAct=EBI-347088, EBI-11977221;
CC       P63104; P30304: CDC25A; NbExp=2; IntAct=EBI-347088, EBI-747671;
CC       P63104; P30305: CDC25B; NbExp=7; IntAct=EBI-347088, EBI-1051746;
CC       P63104; Q00537: CDK17; NbExp=3; IntAct=EBI-347088, EBI-624648;
CC       P63104; Q07002: CDK18; NbExp=2; IntAct=EBI-347088, EBI-746238;
CC       P63104; P23528: CFL1; NbExp=3; IntAct=EBI-347088, EBI-352733;
CC       P63104; Q9P2M7: CGN; NbExp=3; IntAct=EBI-347088, EBI-79537;
CC       P63104; P31327: CPS1; NbExp=2; IntAct=EBI-347088, EBI-536811;
CC       P63104; Q7Z401: DENND4A; NbExp=2; IntAct=EBI-347088, EBI-1046479;
CC       P63104; Q9NRI5: DISC1; NbExp=3; IntAct=EBI-347088, EBI-529989;
CC       P63104; P68104: EEF1A1; NbExp=2; IntAct=EBI-347088, EBI-352162;
CC       P63104; P00533: EGFR; NbExp=6; IntAct=EBI-347088, EBI-297353;
CC       P63104; P06733: ENO1; NbExp=2; IntAct=EBI-347088, EBI-353877;
CC       P63104; Q12778: FOXO1; NbExp=3; IntAct=EBI-347088, EBI-1108782;
CC       P63104; O43524: FOXO3; NbExp=3; IntAct=EBI-347088, EBI-1644164;
CC       P63104; Q16658: FSCN1; NbExp=3; IntAct=EBI-347088, EBI-351076;
CC       P63104; P30793: GCH1; NbExp=4; IntAct=EBI-347088, EBI-958183;
CC       P63104; Q9Y4H4: GPSM3; NbExp=5; IntAct=EBI-347088, EBI-347538;
CC       P63104; P49841: GSK3B; NbExp=4; IntAct=EBI-347088, EBI-373586;
CC       P63104; P0C0S8: H2AC17; NbExp=2; IntAct=EBI-347088, EBI-1390628;
CC       P63104; P68431: H3C12; NbExp=3; IntAct=EBI-347088, EBI-79722;
CC       P63104; P62805: H4C9; NbExp=3; IntAct=EBI-347088, EBI-302023;
CC       P63104; P56524: HDAC4; NbExp=6; IntAct=EBI-347088, EBI-308629;
CC       P63104; Q9UQL6: HDAC5; NbExp=3; IntAct=EBI-347088, EBI-715576;
CC       P63104; Q8WUI4: HDAC7; NbExp=4; IntAct=EBI-347088, EBI-1048378;
CC       P63104; Q9Y4D8: HECTD4; NbExp=2; IntAct=EBI-347088, EBI-7195436;
CC       P63104; P07910: HNRNPC; NbExp=2; IntAct=EBI-347088, EBI-357966;
CC       P63104; P04792: HSPB1; NbExp=4; IntAct=EBI-347088, EBI-352682;
CC       P63104; Q9Y4H2: IRS2; NbExp=3; IntAct=EBI-347088, EBI-1049582;
CC       P63104; Q02241: KIF23; NbExp=6; IntAct=EBI-347088, EBI-306852;
CC       P63104; P33176: KIF5B; NbExp=2; IntAct=EBI-347088, EBI-355878;
CC       P63104; Q9H0B6: KLC2; NbExp=2; IntAct=EBI-347088, EBI-726994;
CC       P63104; Q6P597: KLC3; NbExp=2; IntAct=EBI-347088, EBI-1643885;
CC       P63104; P02545: LMNA; NbExp=2; IntAct=EBI-347088, EBI-351935;
CC       P63104; Q8TBB1: LNX1; NbExp=3; IntAct=EBI-347088, EBI-739832;
CC       P63104; Q5S007: LRRK2; NbExp=11; IntAct=EBI-347088, EBI-5323863;
CC       P63104; Q9NYL2: MAP3K20; NbExp=5; IntAct=EBI-347088, EBI-602273;
CC       P63104; Q99759: MAP3K3; NbExp=2; IntAct=EBI-347088, EBI-307281;
CC       P63104; Q99683: MAP3K5; NbExp=4; IntAct=EBI-347088, EBI-476263;
CC       P63104; P10636: MAPT; NbExp=8; IntAct=EBI-347088, EBI-366182;
CC       P63104; P10636-2: MAPT; NbExp=2; IntAct=EBI-347088, EBI-7796412;
CC       P63104; P10636-3: MAPT; NbExp=9; IntAct=EBI-347088, EBI-7145070;
CC       P63104; Q7KZI7: MARK2; NbExp=7; IntAct=EBI-347088, EBI-516560;
CC       P63104; P27448: MARK3; NbExp=11; IntAct=EBI-347088, EBI-707595;
CC       P63104; O15151: MDM4; NbExp=2; IntAct=EBI-347088, EBI-398437;
CC       P63104; Q6WCQ1: MPRIP; NbExp=2; IntAct=EBI-347088, EBI-1022605;
CC       P63104; O75592: MYCBP2; NbExp=2; IntAct=EBI-347088, EBI-1043774;
CC       P63104; O95544: NADK; NbExp=2; IntAct=EBI-347088, EBI-743949;
CC       P63104; P19338: NCL; NbExp=2; IntAct=EBI-347088, EBI-346967;
CC       P63104; P06748: NPM1; NbExp=2; IntAct=EBI-347088, EBI-78579;
CC       P63104; O96013: PAK4; NbExp=2; IntAct=EBI-347088, EBI-713738;
CC       P63104; Q8TEW0: PARD3; NbExp=5; IntAct=EBI-347088, EBI-81968;
CC       P63104; O60825: PFKFB2; NbExp=2; IntAct=EBI-347088, EBI-764425;
CC       P63104; O00750: PIK3C2B; NbExp=2; IntAct=EBI-347088, EBI-641107;
CC       P63104; O95685: PPP1R3D; NbExp=3; IntAct=EBI-347088, EBI-1045661;
CC       P63104; Q02156: PRKCE; NbExp=7; IntAct=EBI-347088, EBI-706254;
CC       P63104; P16471: PRLR; NbExp=3; IntAct=EBI-347088, EBI-476182;
CC       P63104; O14744: PRMT5; NbExp=2; IntAct=EBI-347088, EBI-351098;
CC       P63104; P26045: PTPN3; NbExp=4; IntAct=EBI-347088, EBI-1047946;
CC       P63104; P04049: RAF1; NbExp=15; IntAct=EBI-347088, EBI-365996;
CC       P63104; Q9P0K7: RAI14; NbExp=2; IntAct=EBI-347088, EBI-1023749;
CC       P63104; Q8NFH8-2: REPS2; NbExp=2; IntAct=EBI-347088, EBI-8029141;
CC       P63104; P61587: RND3; NbExp=11; IntAct=EBI-347088, EBI-1111534;
CC       P63104; P23396: RPS3; NbExp=2; IntAct=EBI-347088, EBI-351193;
CC       P63104; Q5PRF9: SAMD4B; NbExp=2; IntAct=EBI-347088, EBI-1047489;
CC       P63104; P31947: SFN; NbExp=3; IntAct=EBI-347088, EBI-476295;
CC       P63104; Q7L8J4: SH3BP5L; NbExp=2; IntAct=EBI-347088, EBI-747389;
CC       P63104; P57059: SIK1; NbExp=4; IntAct=EBI-347088, EBI-1181640;
CC       P63104; Q9Y2K2: SIK3; NbExp=5; IntAct=EBI-347088, EBI-1181460;
CC       P63104; O60292: SIPA1L3; NbExp=2; IntAct=EBI-347088, EBI-2559690;
CC       P63104; O94875: SORBS2; NbExp=2; IntAct=EBI-347088, EBI-311323;
CC       P63104; Q7Z6B7: SRGAP1; NbExp=2; IntAct=EBI-347088, EBI-2481729;
CC       P63104; O75044: SRGAP2; NbExp=2; IntAct=EBI-347088, EBI-1051034;
CC       P63104; Q15831: STK11; NbExp=6; IntAct=EBI-347088, EBI-306838;
CC       P63104; O00506: STK25; NbExp=2; IntAct=EBI-347088, EBI-618295;
CC       P63104; O60343: TBC1D4; NbExp=2; IntAct=EBI-347088, EBI-522028;
CC       P63104; P36897: TGFBR1; NbExp=4; IntAct=EBI-347088, EBI-1027557;
CC       P63104; P04637: TP53; NbExp=2; IntAct=EBI-347088, EBI-366083;
CC       P63104; Q13625: TP53BP2; NbExp=3; IntAct=EBI-347088, EBI-77642;
CC       P63104; P49815: TSC2; NbExp=7; IntAct=EBI-347088, EBI-396587;
CC       P63104; P40818: USP8; NbExp=2; IntAct=EBI-347088, EBI-1050865;
CC       P63104; P55072: VCP; NbExp=2; IntAct=EBI-347088, EBI-355164;
CC       P63104; P08670: VIM; NbExp=2; IntAct=EBI-347088, EBI-353844;
CC       P63104; P30291: WEE1; NbExp=3; IntAct=EBI-347088, EBI-914695;
CC       P63104; O14980: XPO1; NbExp=2; IntAct=EBI-347088, EBI-355867;
CC       P63104; P46937: YAP1; NbExp=9; IntAct=EBI-347088, EBI-1044059;
CC       P63104; P62258: YWHAE; NbExp=9; IntAct=EBI-347088, EBI-356498;
CC       P63104; P63104: YWHAZ; NbExp=3; IntAct=EBI-347088, EBI-347088;
CC       P63104; Q29495: AANAT; Xeno; NbExp=3; IntAct=EBI-347088, EBI-446413;
CC       P63104; Q61337: Bad; Xeno; NbExp=3; IntAct=EBI-347088, EBI-400328;
CC       P63104; P67828: CSNK1A1; Xeno; NbExp=4; IntAct=EBI-347088, EBI-7540603;
CC       P63104; P54256-2: Hap1; Xeno; NbExp=4; IntAct=EBI-347088, EBI-994554;
CC       P63104; P29172: MAPT; Xeno; NbExp=2; IntAct=EBI-347088, EBI-7291149;
CC       P63104; P61588: Rnd3; Xeno; NbExp=3; IntAct=EBI-347088, EBI-6930266;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17081065}.
CC       Melanosome {ECO:0000269|PubMed:17081065}. Note=Located to stage I to
CC       stage IV melanosomes.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P63104-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P63104-2; Sequence=VSP_047505;
CC   -!- PTM: The delta, brain-specific form differs from the zeta form in being
CC       phosphorylated (By similarity). Phosphorylation on Ser-184 by MAPK8;
CC       promotes dissociation of BAX and translocation of BAX to mitochondria.
CC       Phosphorylation on Thr-232; inhibits binding of RAF1. Phosphorylated on
CC       Ser-58 by PKA and protein kinase C delta type catalytic subunit in a
CC       sphingosine-dependent fashion. Phosphorylation on Ser-58 by PKA;
CC       disrupts homodimerization and heterodimerization with YHAE and TP53.
CC       {ECO:0000250, ECO:0000269|PubMed:11956222, ECO:0000269|PubMed:12865427,
CC       ECO:0000269|PubMed:15071501, ECO:0000269|PubMed:15696159,
CC       ECO:0000269|PubMed:15883165, ECO:0000269|PubMed:16376338,
CC       ECO:0000269|PubMed:9360956}.
CC   -!- SIMILARITY: Belongs to the 14-3-3 family. {ECO:0000305}.
CC   -!- CAUTION: Was originally thought to have phospholipase A2 activity.
CC       {ECO:0000305|PubMed:1577711}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH51814.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAH73141.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M86400; AAA36446.1; -; mRNA.
DR   EMBL; U28964; AAC52052.1; -; mRNA.
DR   EMBL; AK289945; BAF82634.1; -; mRNA.
DR   EMBL; AK296902; BAH12451.1; -; mRNA.
DR   EMBL; CH471060; EAW91823.1; -; Genomic_DNA.
DR   EMBL; BC003623; AAH03623.3; -; mRNA.
DR   EMBL; BC051814; AAH51814.1; ALT_INIT; mRNA.
DR   EMBL; BC063824; AAH63824.2; -; mRNA.
DR   EMBL; BC068456; AAH68456.2; -; mRNA.
DR   EMBL; BC072426; AAH72426.2; -; mRNA.
DR   EMBL; BC073141; AAH73141.1; ALT_INIT; mRNA.
DR   EMBL; BC083508; AAH83508.2; -; mRNA.
DR   EMBL; BC099904; AAH99904.1; -; mRNA.
DR   EMBL; BC101483; AAI01484.1; -; mRNA.
DR   EMBL; BC108281; AAI08282.1; -; mRNA.
DR   EMBL; BC111951; AAI11952.1; -; mRNA.
DR   CCDS; CCDS6290.1; -. [P63104-1]
DR   PIR; A38246; PSHUAM.
DR   RefSeq; NP_001129171.1; NM_001135699.1. [P63104-1]
DR   RefSeq; NP_001129172.1; NM_001135700.1. [P63104-1]
DR   RefSeq; NP_001129173.1; NM_001135701.1. [P63104-1]
DR   RefSeq; NP_001129174.1; NM_001135702.1. [P63104-1]
DR   RefSeq; NP_003397.1; NM_003406.3. [P63104-1]
DR   RefSeq; NP_663723.1; NM_145690.2. [P63104-1]
DR   RefSeq; XP_005251118.1; XM_005251061.3. [P63104-1]
DR   RefSeq; XP_005251120.1; XM_005251063.3. [P63104-1]
DR   RefSeq; XP_016869299.1; XM_017013810.1. [P63104-1]
DR   RefSeq; XP_016869300.1; XM_017013811.1. [P63104-1]
DR   PDB; 1IB1; X-ray; 2.70 A; A/B/C/D=1-245.
DR   PDB; 1QJA; X-ray; 2.00 A; A/B=1-245.
DR   PDB; 1QJB; X-ray; 2.00 A; A/B=1-245.
DR   PDB; 2C1J; X-ray; 2.60 A; A/B=1-245.
DR   PDB; 2C1N; X-ray; 2.00 A; A/B=1-245.
DR   PDB; 2O02; X-ray; 1.50 A; A/B=1-230.
DR   PDB; 2WH0; X-ray; 2.25 A; A/B/C/D=1-245.
DR   PDB; 3CU8; X-ray; 2.40 A; A/B=1-245.
DR   PDB; 3NKX; X-ray; 2.40 A; A/B=1-245.
DR   PDB; 3RDH; X-ray; 2.39 A; A/B/C/D=1-245.
DR   PDB; 4BG6; X-ray; 2.30 A; A/B=1-245.
DR   PDB; 4FJ3; X-ray; 1.95 A; A/B=1-230.
DR   PDB; 4HKC; X-ray; 2.20 A; A=1-245.
DR   PDB; 4IHL; X-ray; 2.20 A; A/B=1-230.
DR   PDB; 4N7G; X-ray; 2.25 A; A=1-230.
DR   PDB; 4N7Y; X-ray; 2.16 A; A/B=1-230.
DR   PDB; 4N84; X-ray; 2.50 A; A/B=1-230.
DR   PDB; 4WRQ; X-ray; 2.41 A; A/B=1-245.
DR   PDB; 4ZDR; X-ray; 2.90 A; A/B=1-230.
DR   PDB; 5D2D; X-ray; 2.10 A; A/B=1-230.
DR   PDB; 5D3F; X-ray; 2.74 A; A/B=1-230.
DR   PDB; 5EWZ; X-ray; 2.34 A; A/B=1-230.
DR   PDB; 5EXA; X-ray; 1.95 A; A/B=1-230.
DR   PDB; 5J31; X-ray; 2.40 A; A/B=1-230.
DR   PDB; 5JM4; X-ray; 2.34 A; A/B=1-229.
DR   PDB; 5M35; X-ray; 2.38 A; A/B=2-230.
DR   PDB; 5M36; X-ray; 2.45 A; A/B=2-230.
DR   PDB; 5M37; X-ray; 2.35 A; A/B=1-230.
DR   PDB; 5NAS; X-ray; 2.08 A; A/B=1-230.
DR   PDB; 5ULO; X-ray; 2.14 A; A/B=1-245.
DR   PDB; 5WXN; X-ray; 2.93 A; A/B=1-245.
DR   PDB; 5XY9; X-ray; 2.30 A; A/B=1-245.
DR   PDB; 6EF5; X-ray; 2.44 A; A/B/C/D=1-245.
DR   PDB; 6EJL; X-ray; 2.38 A; A/B=1-230.
DR   PDB; 6EWW; X-ray; 2.68 A; A/B/C/D=1-230.
DR   PDB; 6F08; X-ray; 1.90 A; A/B/I/J=1-230.
DR   PDB; 6F09; X-ray; 1.59 A; P/Q/R/S=1-230.
DR   PDB; 6FN9; X-ray; 2.27 A; A/B=1-230.
DR   PDB; 6FNA; X-ray; 2.12 A; A/B=1-230.
DR   PDB; 6FNB; X-ray; 2.30 A; A/B=1-230.
DR   PDB; 6FNC; X-ray; 2.12 A; A/B=1-230.
DR   PDB; 6Q0K; EM; 6.80 A; X/Y=1-245.
DR   PDB; 6RLZ; X-ray; 3.70 A; A/B=1-230.
DR   PDB; 6U2H; X-ray; 2.50 A; A/B=1-230.
DR   PDB; 6XAG; X-ray; 3.30 A; A/B=1-230.
DR   PDBsum; 1IB1; -.
DR   PDBsum; 1QJA; -.
DR   PDBsum; 1QJB; -.
DR   PDBsum; 2C1J; -.
DR   PDBsum; 2C1N; -.
DR   PDBsum; 2O02; -.
DR   PDBsum; 2WH0; -.
DR   PDBsum; 3CU8; -.
DR   PDBsum; 3NKX; -.
DR   PDBsum; 3RDH; -.
DR   PDBsum; 4BG6; -.
DR   PDBsum; 4FJ3; -.
DR   PDBsum; 4HKC; -.
DR   PDBsum; 4IHL; -.
DR   PDBsum; 4N7G; -.
DR   PDBsum; 4N7Y; -.
DR   PDBsum; 4N84; -.
DR   PDBsum; 4WRQ; -.
DR   PDBsum; 4ZDR; -.
DR   PDBsum; 5D2D; -.
DR   PDBsum; 5D3F; -.
DR   PDBsum; 5EWZ; -.
DR   PDBsum; 5EXA; -.
DR   PDBsum; 5J31; -.
DR   PDBsum; 5JM4; -.
DR   PDBsum; 5M35; -.
DR   PDBsum; 5M36; -.
DR   PDBsum; 5M37; -.
DR   PDBsum; 5NAS; -.
DR   PDBsum; 5ULO; -.
DR   PDBsum; 5WXN; -.
DR   PDBsum; 5XY9; -.
DR   PDBsum; 6EF5; -.
DR   PDBsum; 6EJL; -.
DR   PDBsum; 6EWW; -.
DR   PDBsum; 6F08; -.
DR   PDBsum; 6F09; -.
DR   PDBsum; 6FN9; -.
DR   PDBsum; 6FNA; -.
DR   PDBsum; 6FNB; -.
DR   PDBsum; 6FNC; -.
DR   PDBsum; 6Q0K; -.
DR   PDBsum; 6RLZ; -.
DR   PDBsum; 6U2H; -.
DR   PDBsum; 6XAG; -.
DR   BMRB; P63104; -.
DR   SMR; P63104; -.
DR   BioGRID; 113366; 627.
DR   ComplexPortal; CPX-1147; FOXO3-YWHAZ complex.
DR   CORUM; P63104; -.
DR   DIP; DIP-563N; -.
DR   ELM; P63104; -.
DR   IntAct; P63104; 713.
DR   MINT; P63104; -.
DR   STRING; 9606.ENSP00000379287; -.
DR   BindingDB; P63104; -.
DR   ChEMBL; CHEMBL4105899; -.
DR   DrugBank; DB12695; Phenethyl Isothiocyanate.
DR   MoonDB; P63104; Predicted.
DR   TCDB; 8.A.98.1.2; the 14-3-3 protein (14-3-3) family.
DR   iPTMnet; P63104; -.
DR   MetOSite; P63104; -.
DR   PhosphoSitePlus; P63104; -.
DR   SwissPalm; P63104; -.
DR   BioMuta; YWHAZ; -.
DR   DMDM; 52000887; -.
DR   DOSAC-COBS-2DPAGE; P63104; -.
DR   OGP; P63104; -.
DR   UCD-2DPAGE; P63104; -.
DR   EPD; P63104; -.
DR   jPOST; P63104; -.
DR   MassIVE; P63104; -.
DR   MaxQB; P63104; -.
DR   PaxDb; P63104; -.
DR   PeptideAtlas; P63104; -.
DR   PRIDE; P63104; -.
DR   ProteomicsDB; 57477; -.
DR   TopDownProteomics; P63104-1; -. [P63104-1]
DR   Antibodypedia; 3905; 984 antibodies.
DR   DNASU; 7534; -.
DR   Ensembl; ENST00000353245; ENSP00000309503; ENSG00000164924. [P63104-1]
DR   Ensembl; ENST00000395951; ENSP00000379281; ENSG00000164924. [P63104-1]
DR   Ensembl; ENST00000395953; ENSP00000379283; ENSG00000164924. [P63104-1]
DR   Ensembl; ENST00000395956; ENSP00000379286; ENSG00000164924. [P63104-1]
DR   Ensembl; ENST00000395957; ENSP00000379287; ENSG00000164924. [P63104-1]
DR   Ensembl; ENST00000395958; ENSP00000379288; ENSG00000164924. [P63104-1]
DR   Ensembl; ENST00000419477; ENSP00000395114; ENSG00000164924. [P63104-1]
DR   Ensembl; ENST00000457309; ENSP00000398599; ENSG00000164924. [P63104-1]
DR   Ensembl; ENST00000522542; ENSP00000430072; ENSG00000164924. [P63104-2]
DR   GeneID; 7534; -.
DR   KEGG; hsa:7534; -.
DR   UCSC; uc003yjv.3; human. [P63104-1]
DR   CTD; 7534; -.
DR   DisGeNET; 7534; -.
DR   GeneCards; YWHAZ; -.
DR   HGNC; HGNC:12855; YWHAZ.
DR   HPA; ENSG00000164924; Low tissue specificity.
DR   MIM; 601288; gene.
DR   neXtProt; NX_P63104; -.
DR   OpenTargets; ENSG00000164924; -.
DR   PharmGKB; PA37444; -.
DR   VEuPathDB; HostDB:ENSG00000164924.17; -.
DR   eggNOG; KOG0841; Eukaryota.
DR   GeneTree; ENSGT01000000214500; -.
DR   InParanoid; P63104; -.
DR   PhylomeDB; P63104; -.
DR   TreeFam; TF102003; -.
DR   PathwayCommons; P63104; -.
DR   Reactome; R-HSA-111447; Activation of BAD and translocation to mitochondria.
DR   Reactome; R-HSA-1445148; Translocation of SLC2A4 (GLUT4) to the plasma membrane.
DR   Reactome; R-HSA-3769402; Deactivation of the beta-catenin transactivating complex.
DR   Reactome; R-HSA-392517; Rap1 signalling.
DR   Reactome; R-HSA-430116; GP1b-IX-V activation signalling.
DR   Reactome; R-HSA-450604; KSRP (KHSRP) binds and destabilizes mRNA.
DR   Reactome; R-HSA-512988; Interleukin-3, Interleukin-5 and GM-CSF signaling.
DR   Reactome; R-HSA-5625740; RHO GTPases activate PKNs.
DR   Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes.
DR   Reactome; R-HSA-75035; Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex.
DR   Reactome; R-HSA-9013700; NOTCH4 Activation and Transmission of Signal to the Nucleus.
DR   Reactome; R-HSA-9604323; Negative regulation of NOTCH4 signaling.
DR   Reactome; R-HSA-9614399; Regulation of localization of FOXO transcription factors.
DR   SignaLink; P63104; -.
DR   SIGNOR; P63104; -.
DR   BioGRID-ORCS; 7534; 154 hits in 945 CRISPR screens.
DR   ChiTaRS; YWHAZ; human.
DR   EvolutionaryTrace; P63104; -.
DR   GeneWiki; YWHAZ; -.
DR   GenomeRNAi; 7534; -.
DR   Pharos; P63104; Tbio.
DR   PRO; PR:P63104; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   RNAct; P63104; protein.
DR   Bgee; ENSG00000164924; Expressed in frontal cortex and 247 other tissues.
DR   ExpressionAtlas; P63104; baseline and differential.
DR   Genevisible; P63104; HS.
DR   GO; GO:0072562; C:blood microparticle; HDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; HDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0098978; C:glutamatergic synapse; IDA:SynGO.
DR   GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; IEA:GOC.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; HDA:UniProtKB.
DR   GO; GO:0031982; C:vesicle; HDA:UniProtKB.
DR   GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0044325; F:ion channel binding; IPI:SynGO-UCL.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0002250; P:adaptive immune response; TAS:Reactome.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0051683; P:establishment of Golgi localization; IMP:UniProtKB.
DR   GO; GO:0090168; P:Golgi reassembly; IMP:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; TAS:ProtInc.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:1900740; P:positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0006468; P:protein phosphorylation; IMP:UniProtKB.
DR   GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0043488; P:regulation of mRNA stability; TAS:Reactome.
DR   GO; GO:0090128; P:regulation of synapse maturation; IDA:SynGO.
DR   GO; GO:0007165; P:signal transduction; IMP:UniProtKB.
DR   Gene3D; 1.20.190.20; -; 1.
DR   IDEAL; IID00061; -.
DR   InterPro; IPR000308; 14-3-3.
DR   InterPro; IPR023409; 14-3-3_CS.
DR   InterPro; IPR036815; 14-3-3_dom_sf.
DR   InterPro; IPR023410; 14-3-3_domain.
DR   PANTHER; PTHR18860; PTHR18860; 1.
DR   Pfam; PF00244; 14-3-3; 1.
DR   PIRSF; PIRSF000868; 14-3-3; 1.
DR   PRINTS; PR00305; 1433ZETA.
DR   SMART; SM00101; 14_3_3; 1.
DR   SUPFAM; SSF48445; SSF48445; 1.
DR   PROSITE; PS00796; 1433_1; 1.
DR   PROSITE; PS00797; 1433_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Cytoplasm;
KW   Direct protein sequencing; Disease variant; Phosphoprotein;
KW   Reference proteome.
FT   CHAIN           1..245
FT                   /note="14-3-3 protein zeta/delta"
FT                   /id="PRO_0000058627"
FT   SITE            56
FT                   /note="Interaction with phosphoserine on interacting
FT                   protein"
FT                   /evidence="ECO:0000250"
FT   SITE            127
FT                   /note="Interaction with phosphoserine on interacting
FT                   protein"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0000269|Ref.8, ECO:0007744|PubMed:22223895,
FT                   ECO:0007744|PubMed:22814378, ECO:0007744|PubMed:25944712"
FT   MOD_RES         3
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         58
FT                   /note="Phosphoserine; by PKA and PKB/AKT1"
FT                   /evidence="ECO:0000269|PubMed:11956222,
FT                   ECO:0000269|PubMed:12865427, ECO:0000269|PubMed:15883165,
FT                   ECO:0000269|PubMed:16376338"
FT   MOD_RES         68
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         184
FT                   /note="Phosphoserine; by MAPK8"
FT                   /evidence="ECO:0000269|PubMed:15071501,
FT                   ECO:0000269|PubMed:15696159"
FT   MOD_RES         207
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         210
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P63102"
FT   MOD_RES         232
FT                   /note="Phosphothreonine; by CK1"
FT                   /evidence="ECO:0000269|PubMed:31024343,
FT                   ECO:0000269|PubMed:9360956, ECO:0007744|PubMed:20068231"
FT   VAR_SEQ         1..98
FT                   /note="MDKNELVQKAKLAEQAERYDDMAACMKSVTEQGAELSNEERNLLSVAYKNVV
FT                   GARRSSWRVVSSIEQKTEGAEKKQQMAREYREKIETELRDICNDVL -> MSQPCRKLW
FT                   RHNYETSSCIEFLK (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_047505"
FT   VARIANT         14..245
FT                   /note="Missing (found in a patient with a
FT                   neurodevelopmental disorder; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:31024343"
FT                   /id="VAR_082640"
FT   VARIANT         53
FT                   /note="G -> R (found in a patient with a neurodevelopmental
FT                   disorder; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:31024343"
FT                   /id="VAR_082641"
FT   VARIANT         145
FT                   /note="S -> L (found in a patient with a neurodevelopmental
FT                   disorder; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:31024343"
FT                   /id="VAR_082642"
FT   VARIANT         230
FT                   /note="S -> W (found in a patient with a neurodevelopmental
FT                   disorder; unknown pathological significance; gain-of-
FT                   function mutation in signal transduction; changed
FT                   regulation of ERK1 and ERK2 cascade; increased interaction
FT                   with BRAF; increased interaction with RAF1; loss of
FT                   phosphorylation by CK1 at Thr-232)"
FT                   /evidence="ECO:0000269|PubMed:31024343"
FT                   /id="VAR_082643"
FT   MUTAGEN         49
FT                   /note="K->E: Loss of interaction with NOXA1."
FT                   /evidence="ECO:0000269|PubMed:17913709"
FT   MUTAGEN         56..60
FT                   /note="RSSWR->ASSWA: Abolishes lamellipodia formation and
FT                   induces filopodia formation."
FT                   /evidence="ECO:0000269|PubMed:16959763"
FT   MUTAGEN         58
FT                   /note="S->A: Loss of sphingosine-activated PKA
FT                   phosphorylation. Promotes homodimerization and
FT                   heterodimerization with YWHAE. Enhanced transcriptional
FT                   activity of P53."
FT                   /evidence="ECO:0000269|PubMed:15883165,
FT                   ECO:0000269|PubMed:16376338"
FT   MUTAGEN         58
FT                   /note="S->E: Loss of homodimerization. Reduced dimerization
FT                   with YWHAE. Significantly reduced interaction with P53. No
FT                   enhancement of P53 transcriptional activity."
FT                   /evidence="ECO:0000269|PubMed:15883165,
FT                   ECO:0000269|PubMed:16376338"
FT   MUTAGEN         184
FT                   /note="S->A: On DNA damage, loss of MAPK8-mediated
FT                   phosphorylation. Loss of binding ABL1. Attenuates ABL1-
FT                   mediated apoptosis. No loss of interaction with BAX under
FT                   stress conditions. Inhibits translocation of BAX to
FT                   mitochondria."
FT                   /evidence="ECO:0000269|PubMed:15071501,
FT                   ECO:0000269|PubMed:15696159"
FT   MUTAGEN         232
FT                   /note="T->A: Loss of phosphorylation by CK1."
FT                   /evidence="ECO:0000269|PubMed:31024343"
FT   CONFLICT        22
FT                   /note="M -> V (in Ref. 5; AAH68456)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        136
FT                   /note="D -> G (in Ref. 3; BAH12451)"
FT                   /evidence="ECO:0000305"
FT   HELIX           3..15
FT                   /evidence="ECO:0007744|PDB:2O02"
FT   HELIX           19..31
FT                   /evidence="ECO:0007744|PDB:2O02"
FT   HELIX           38..67
FT                   /evidence="ECO:0007744|PDB:2O02"
FT   TURN            69..71
FT                   /evidence="ECO:0007744|PDB:2O02"
FT   HELIX           76..103
FT                   /evidence="ECO:0007744|PDB:2O02"
FT   HELIX           105..108
FT                   /evidence="ECO:0007744|PDB:2O02"
FT   HELIX           112..131
FT                   /evidence="ECO:0007744|PDB:2O02"
FT   HELIX           135..159
FT                   /evidence="ECO:0007744|PDB:2O02"
FT   HELIX           165..180
FT                   /evidence="ECO:0007744|PDB:2O02"
FT   HELIX           185..200
FT                   /evidence="ECO:0007744|PDB:2O02"
FT   HELIX           201..205
FT                   /evidence="ECO:0007744|PDB:2O02"
FT   TURN            208..210
FT                   /evidence="ECO:0007744|PDB:2O02"
FT   HELIX           211..228
FT                   /evidence="ECO:0007744|PDB:2O02"
SQ   SEQUENCE   245 AA;  27745 MW;  D464DF2286BBFE60 CRC64;
     MDKNELVQKA KLAEQAERYD DMAACMKSVT EQGAELSNEE RNLLSVAYKN VVGARRSSWR
     VVSSIEQKTE GAEKKQQMAR EYREKIETEL RDICNDVLSL LEKFLIPNAS QAESKVFYLK
     MKGDYYRYLA EVAAGDDKKG IVDQSQQAYQ EAFEISKKEM QPTHPIRLGL ALNFSVFYYE
     ILNSPEKACS LAKTAFDEAI AELDTLSEES YKDSTLIMQL LRDNLTLWTS DTQGDEAEAG
     EGGEN
//
